Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI

被引：0

作者：

Berges R. ^{[1
]}

Schremmer D. ^{[2
]}

Limberg R. ^{[3
]}

机构：

[1] Urologe, PAN-Klinik, Köln

[2] GKM — Gesellschaft für Therapieforschung mbH, Lessingstr. 14, München

[3] Berlin-Chemie AG, Berlin

来源：

MMW - Fortschritte der Medizin | 2017年 / 159卷 / Suppl 5期

关键词：

Avanafil; erectile dysfunction; PDE-5; inhibitor;

D O I：

10.1007/s15006-017-9804-1

中图分类号：

学科分类号：

摘要：

Objective and method: In the prospective, multicentric, non-interventional AVANTI study, the selection criteria for the PDE-5 inhibitor Avanafil were evaluated and it's acceptance in the treatment of patients with erectile dysfunction was investigated. Data from 1,804 probands with an average age of 58.0 years were analyzed. Results: Doctors and patients most commonly referred to Avanafil as a fast-acting substance (70.6% and 78.6%, respectively). A favorable side-effect profile was more focused when the patient co-decided (62.7%) than if the doctor selected (48.4%). 41.2% of the physicians emphasized the potency, 56.7% of the patients preferred to receive a modern medicine. Doctors and patients assessed the drug as effective and well tolerated. © 2017, Springer Medizin.

引用

页码：16 / 21

页数：5

共 32 条

[1]

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology, Aarnheim/The Nederlands, (2015)

[2]

Eardley I., The incidence, prevalence, and natural history of erectile dysfunction, Sex Med Rev, 1, pp. 3-16, (2013)

[3]

Braun M., Wassmer G., Klotz T., Et al., Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’, Int J Impot Res, 12, 6, pp. 305-311, (2000)

[4]

Capogrosso P., Colicchia M., Ventimiglia E., Et al., One patient out of four with newly diagnosed erectile dysfunction is a young man — worrisome picture from the everyday clinical practice, J Sex Med, 10, 7, pp. 1833-1841, (2013)

[5]

Capogrosso P., Montorsi F., Salonia A., Erectile dysfunction in young patients is a proxy of overall men’s health status, Curr Opin Urol, 26, 2, pp. 140-145, (2016)

[6]

Rosen R., Eardley I., Et al., The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population, Curr Med Res Opin, 20, 5, pp. 607-617, (2004)

[7]

Montague D.K., Jarow J.P., Broderick G.A., Et al., Chapter 1: The management of erectile dysfunction: an AUA update, J Urol, 174, 1, pp. 230-239, (2005)

[8]

Porst H., Burnett A., Brock G., Et al., SOP conservative (medical and mechanical) treatment of erectile dysfunction, J Sex Med, 10, 1, pp. 130-171, (2013)

[9]

Mcmahon C.N., Smith C.J., Shabsigh R., Treating erectile dysfunction when PDE5 inhibitors fail, BMJ, 332, 7541, pp. 589-592, (2006)

[10]

Carvalheira A.A., Pereira N.M., Maroco J., Et al., Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation, J Med Sex, 9, 9, pp. 2361-2369, (2012)

← 1 2 3 4 →